Table 2.
Characteristics of Patients with AML by FLT3 mutation
| a. Patients with CBF-AML | |||
|---|---|---|---|
| Parameter | Median [Range] or No. (%) | p | |
| FLT3-Mutated (N =13) | wt-FLT3 (N = 52) | ||
| Age, years | 50 [19–80] | 49.5 [18–88] | 0.95 |
| Male Sex | 9 (69) | 27 (52) | 0.35 |
| White Race | 9 (69) | 33 (63) | 0.76 |
| ECOG PS 3–4 | 0 (0) | 1 (2) | 1.0 |
| Hb, g/dL | 8.5 [6.7–10.6] | 8.8 [5.1–13.1] | 0.54 |
| WBC, × 109/L | 37 [3.9–89.5] | 14 [0.6–14.6] | 0.019 |
| Platelets, × 109/L | 38 [17–135] | 42.5 [4–330] | 0.66 |
| BM Blasts, % | 76 [21–91] | 50.5 [10–92] | 0.006 |
| Creatinine, mg/dL | 1.0 [0.5–1.7] | 1.0 [0.4–5.2] | 0.82 |
| Bilirubin, mg/dL | 0.6 (0.3–1.0) | 0.5 (0.1–4.7) | 0.41 |
| Cytogenetics | 0.02 | ||
| • t(8;21) | 2 (15) | 27 (52) | |
| • inv(16)/t(16;16) | 11 (85) | 25 (48) | |
| AHD | 4 (31) | 9 (17) | 0.27 |
| Previous Chemo/XRT | 0 (0) | 5 (10) | 0.57 |
| Treatment Regimens | 1.0 | ||
| • With Ara-C | 13 (100) | 52 (100) | |
| CR Rate | 92% | 90% | 1.0 |
| b. Patients with NK-AML | |||||
|---|---|---|---|---|---|
| Parameter | Median [Range] or No. (%) | p (ITD vs WT) | p (TKD vs WT) | ||
| FLT3-ITD (N = 69)1 | FLT3-TKD (N = 18) | wt-FLT3 (N = 185) | |||
| Age, years | 58 [17–84] | 62 [28–78] | 61 [18–83] | 0.12 | 0.91 |
| Male Sex | 33 (48) | 10 (55) | 99 (54) | 0.48 | 1.0 |
| White Race | 52 (75) | 17 (94) | 148 (80) | 0.49 | 0.20 |
| ECOG PS 3–4 | 0 (0) | 2 (11) | 3 (2) | 0.56 | 0.05 |
| Hb, g/dL | 8.2 [5–11.7] | 7.7 [5–10.6] | 8.4 [4.0–14.2] | 0.43 | 0.03 |
| WBC, × 109/L | 18.1 [1–166] | 22.5 [1.2–291] | 3.3 [0.4–204] | < 0.001 | < 0.001 |
| Platelets, × 109/L | 50 [9–302] | 57.5 [18–119] | 64 [3–469] | 0.13 | 0.27 |
| BM Blasts, % | 70 [8–96] | 65 [24–91] | 44 [3–93] | < 0.001 | 0.01 |
| Creatinine, mg/dL | 0.9 [0.5–2.0] | 1.0 [0.6–2.1] | 0.9 [0.4–6.8] | 0.20 | 0.38 |
| Bilirubin, mg/dL | 0.5 [0.1–2.3] | 0.45 [0.2–1.4] | 0.5 [0.1–10.3] | 0.44 | 0.51 |
| AHD | 27 (39) | 4 (22) | 88 (47.6) | 0.25 | 0.04 |
| Previous Chemo/XRT | 2 (3) | 3 (17) | 22 (11.9) | 0.02 | 0.47 |
| Treatment Regimens | 0.03 | 0.47 | |||
| • With Ara-C | 51 (74) | 17 (94) | 159 6) | ||
| • Without Ara-C | 18 (27) | 1 (6) | 26 (14) | ||
| CR Rate | 58% | 78% | 68% | 0.17 | 0.59 |
| (c). Patients with Poor Risk-AML | |||
|---|---|---|---|
| Parameter | Median [Range] or No. (%) | p | |
| FLT3-mutated (N =11) | wt-FLT3 (N = 133) | ||
| Age, years | 59 [34–83] | 60 [19–85] | 0.9 |
| Male Sex | 9 (82) | 61 (46) | 0.03 |
| White Race | 8 (73) | 101 (76) | 0.73 |
| ECOG PS 3–4 | 0 (0) | 4 (3) | 1.0 |
| Hb, g/dL | 8.5 [5.9–10.4] | 8 [2–14.2] | 0.95 |
| WBC, × 109/L | 8.4 [1.6–119] | 4 [0.8–433] | 0.16 |
| Platelets, × 109/L | 45 [16–117] | 39 [7–762] | 0.86 |
| BM Blasts, % | 55 [10–96] | 40 [5–97] | 0.33 |
| Creatinine, mg/dL | 1.1 [0.7–1.5] | 0.9 [0.5–4.5] | 0.02 |
| Bilirubin, mg/dL | 0.6 [0.3–2.0] | 0.6 [0.1–6.2] | 0.53 |
| Cytogenetics | 0.18 | ||
| • 11q23 | 3 (28) | 17 (13) | |
| • −5/del(5q) and/or −7/del(7q) | 8 (72) | 116 (87) | |
| AHD | 6 (55) | 69 (52) | 1.0 |
| Previous Chemo/XRT | 3 (27) | 36 (27) | 1.0 |
| Treatment Regimens | 0.03 | ||
| • With Ara-C | 6 (55) | 111 4) | |
| • Without Ara-C | 5 (45) | 22 (16) | |
| CR Rate | 18% | 43% | 0.20 |
Abbreviations: AHD, antecedent hematological disorder; BM, bone marrow; Chemo, chemotherapy; Hb, hemoglobin; PS, performance status; WBC, white blood cell count; XRT, radiotherapy.
Abbreviations: AHD, antecedent hematological disorder; BM, bone marrow; Chemo, chemotherapy; Hb, hemoglobin; PS, performance status; WBC, white blood cell count; XRT, radiotherapy.
1
Includes 10 patients with double mutations.
Abbreviations: AHD, antecedent hematological disorder; BM, bone marrow; Chemo, chemotherapy; Hb, hemoglobin; PS, performance status; WBC, white blood cell count; XRT, radiotherapy.